[Medical treatment of osteoporosis in men].
One in five men over the age of 50 years will suffer an osteoporotic fracture during their lifetime, and men who sustain fractures have an increased mortality risk compared to women. Three bisphosphonates (alendronate, risedronate and zolendronic acid), denosumab, strontium ranelate and teriparatide are currently approved in Denmark for the treatment of osteoporosis in men. This review summarizes the available therapeutic options.
Kardiologisk, Nefrologisk, Endokrinologisk Afdeling H 0652, Nordsjællands Hospital Hillerød, Dyrehavevej 29, 3400 Hillerød. pia.eiken@regionh.dk.
Pia A
PA
Eiken
Peter
P
Vestergaard
D000368:Aged; D015519:Bone Density / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control
D050071:Bone Density Conservation Agents